Which antihypertensive drug classes have been shown to be beneficial? What are their benefits? A critique of hypertension treatment trials

Cardiovascular Drugs and Therapy

Volumn 14, Issue 4, 2000, Pages 357-366

  Robertson, J I S ^a  

^a Elmbank   (United Kingdom)

Author keywords

Antihypertensive drugs; Hypertension; Meta analysis; Treatment trials

Indexed keywords

ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; PROPRANOLOL; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLEEDING; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT INDICATION;

ADULT; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; HYPERTENSION; MALE; META-ANALYSIS; MIDDLE AGED; RISK FACTORS;

EID: 0033845927     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007851913672     Document Type: Conference Paper

References (99)

1. Hypertension
2. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
3. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease
4. Medical Research Council trial of treatment in older adults: Principal results
5. The role of blood pressure control in preventing complications of hypertension
6. Effects of treatment in hypertension: Results of a controlled study
7. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mmHg
8. Control of moderately raised blood pressure: Report of a co-operative randomized controlled trial
9. Hypotensive therapy in stroke survivors
10. Effect of antihypertensive therapy on stroke recurrence
11. Treatment of mild hypertension: Results of a ten-year intervention trial
12. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial
13. Treatment of mild hypertension: A five year controlled drug trial: The Oslo study
14. Australian therapeutic trial in mild hypertension
15. MRC trial of treatment of mild hypertension: Principal results
16. Mortality and morbidity results from the European working party on high blood pressure in the Elderly trial
17. Treatment of Mild Hypertension Study: Final results
18. Prospective study on the treatment of mild hypertension in the aged
19. Randomised trial of treatment of hypertension in elderly patients in primary care
20. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study
21. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
22. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
23. Shanghai trial of nifedipine in the elderly (STONE)
24. Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality in persons with high blood pressure, including mild hypertension
25. Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results
26. Blood pressure reduction in the elderly: A randomised controlled trial of methyldopa
27. Multiple Risk Factor Intervention Trial
28. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
29. Update on the Systolic Hypertension in Europe (Syst-Eur) trial
30. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension
31. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
32. JNC VI: Timing is everything
33. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
34. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension
35. 1 receptor agonists: New data on hypertension and related pathologies
36. Guidelines for the treatment of hypertension: A critical review
37. Guidelines contradictions
38. Hypertension - Treated and untreated: A study of 400 cases
39. Merits of reducing high blood pressure
40. Some aspects of prognosis in treated hypertension
41. Risks and benefits of treating mild hypertension: A misleading meta-analysis?
42. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: A review of randomized controlled trials
43. Controlled clinical trials of drug treatment for hypertension: A review
44. The effects of antihypertensive drug treatment on the incidence of stroke and of coronary heart disease
45. New meta-analysis of treatment trials of hypertension: Improving the estimate of benefit
46. Effect of antihypertensive drug treatment on cardiovascular outcomes in men and women: A meta-analysis of individual patient data from randomized, controlled trials
47. Treating mild hypertension. Report of the British Hypertension Society working party
48. Management guidelines in essential hypertension: Report of the second working parity of the British Hypertension Society
49. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-year findings of the Hypertension Detection and Follow-up Program
50. Incidence of coronary heart disease and left ventricular hypertrophy in the Hypertension Detection and Follow-up Program
51. The rationale for differing national recommendations for the treatment of hypertension
52. Antihypertensive drugs in very old people: A subgroup meta-analysis of randomised controlled trials
53. Effect of two different aproaches on total and cardiovascular mortality in a cardiovascular study in the elderly (CASTEL)
54. Evidence is needed that beta-blockade alone reduces mortality in hypertension
55. Subgroup and per-protocol analysis of the randomised European trial of isolated systolic hypertension in the elderly
56. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH)
57. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial
58. Metoprolol versus thiazide diuretics in hypertension: Morbidity results from the MAPHY study
59. British MRC trial of treatment for mild hypertension: A more favorable interpretation
60. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension
61. A meta-analysis of mortality and coronary prevention in hypertensive patients treated with beta-receptor blockers
62. Effect of atenolol and reserpine on selected events in the Systolic Hypertension in the Elderly Program (SHEP)
63. Treatment of mild hypertension with diuretics: The importance of ECG abnormalities in the Oslo study and in MRFIT
64. Effect of risk status on treatment criteria: Implications of hypertension trials
65. Non-potassium-sparing diuretics and risk of sudden cardiac death
66. Treatment of hypertension in the elderly
67. Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure
68. Diuretics, beta-blockers, and the risk of sudden cardiac death in hypertensive patients
69. Diuretic therapy and the risk of primary cardiac arrest
70. Diuretic-induced potassium and magnesium deficiency: Relation to drug-induced QT prolongation, cardiac arrhythmias, and sudden death
71. Do non-potassium sparing diuretics increase the risk of sudden cardiac death in hypertensive patients? New evidence
72. The risk of myocardial infarction associated with antihypertensive drug therapies
73. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
74. Calcium antagonists: Not appropriate as first line antihypertensive agents
75. Calcium antagonists: Still appropriate as first line antihypertensive agents
76. How safe are calcium antagonists in hypertension and coronary heart disease?
77. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?
78. Beta-blockers for hypertension: Time to call a halt
79. Relationship of arterial pressure with body sodium, body potassium, and plasma potassium in essential hypertension
80. How strong is the evidence that recommendations to reduce population average salt intake will reduce mortality from cardiovascular disease?
81. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo
82. Calcium channel blockers: The jury is still out on whether they cause heart attacks and suicide
83. Do inhibitors of anglotensin-I-converting enzyme protect against risk of cancer?
84. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients
85. Risk reduction in treating hypertension - Are there differences between various classes of drugs?
86. Management of raised blood pressure in New Zealand: A discussion document
87. An appraisal of hypertension trials
88. Study to the end of my days
89. Evidence-based medicine and hypertension
90. The rise and fall of Evidence-Based Medicine (EBM)
91. The 1993 treatment guidelines: More criticisms
92. Randomised trial of old and new antihypertensive drugs in elderly patients; cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with hypertension-2 study
93. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The captopril prevention project (CAPPP)
94. Effects of an angiotensin-converting-enzyme inhibitor ramipril on cardiovascular events in high-risk patients
95. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy